Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cardiovascular comorbidities as predictors for severe COVID-19 infection or death

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Significant regional variation in use of implantable cardioverter-defibrillators in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A DANISH national cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of out-of-hospital cardiac arrest in patients with bipolar disorder or schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI) in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, to determine temporal trends and risk factors for non-use.

METHODS AND RESULTS: Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of beta-blockers, aspirin, and statins after hospitalization for first-time MI among patients with and without COPD from 1995 to 2015. Risk factors for non-use were examined in multivariable logistic regression models. During 21 years of study, 140 278 patients were included, hereof 13 496 (9.6%) with COPD. Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P < 0.001), aspirin (73.9% vs. 78.8%, P < 0.001), and statins (53.5% vs. 61.9%, P < 0.001). Medication usage increased during the study period but in multivariable analyses, COPD remained a significant predictor for non-use: odds ratio (95% confidence interval) for non-use of beta-blockers 1.86 (1.76-1.97); aspirin 1.24 (1.16-1.32); statins 1.50 (1.41-1.59). Analyses stratified by ST-segment elevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients. Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, and increasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, and low lung function). Similar findings were demonstrated for aspirin and statins.

CONCLUSION: Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD following hospitalization for MI despite an overall increase in the utilization over time. Increasing severity of COPD was a risk factor for non-use of the medications.

OriginalsprogEngelsk
TidsskriftEuropean heart journal. Quality of care & clinical outcomes
Vol/bind6
Udgave nummer1
Sider (fra-til)23-31
Antal sider9
ISSN2058-5225
DOI
StatusUdgivet - 1 jan. 2020

Bibliografisk note

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

ID: 62030586